IFO
UTHR icon

Intrepid Family Office’s United Therapeutics UTHR Stock Holding History

Intrepid Family Office’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-7,500
Closed -$1.77M – 23
2022
Q2 		$1.77M Buy
+7,500
New +$1.52M 4.56% 10

Other funds holding UTHR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Intrepid Family Office's UTHR Position: Q3 2022 in Review

Intrepid Family Office sold out of United Therapeutics (UTHR) in Q3 2022, closing a stake of 7,500 shares — an estimated $1.77M sold.

Intrepid Family Office first reported a position in UTHR in Q2 2022 and held it in 1 quarter. The position peaked at $1.77M in Q2 2022. 459 funds tracked by Wall St. Rank hold UTHR as of Q3 2022.

  • Intrepid Family Office reported no remaining United Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Intrepid Family Office sold 7,500 United Therapeutics shares in Q3 2022, an estimated $1.77M.
  • Intrepid Family Office first reported a position in United Therapeutics in Q2 2022 and held it in 1 quarter.
  • Intrepid Family Office's United Therapeutics position peaked at $1.77M in Q2 2022.
  • 459 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2022.

Based on Intrepid Family Office's 13F filing for Q3 2022, filed 14 Nov 2022.